PubRank

David J Kerr

Author PubWeight™ 90.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 13.34
2 Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007 9.23
3 Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2012 6.25
4 Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010 4.20
5 Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012 3.19
6 Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013 2.90
7 Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009 2.59
8 Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011 2.55
9 Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 2011 2.47
10 Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010 2.32
11 Open access chemical and clinical probes to support drug discovery. Nat Chem Biol 2009 2.28
12 Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011 2.02
13 The challenge of cancer control in Africa. Nat Rev Cancer 2008 1.71
14 Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004 1.54
15 Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002 1.52
16 A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009 1.46
17 Arginine methylation controls growth regulation by E2F-1. EMBO J 2012 1.44
18 Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol 2010 1.34
19 HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A 2010 1.26
20 Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. J Clin Oncol 2013 1.26
21 Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009 1.15
22 Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005 1.14
23 Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 2011 1.12
24 Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002 1.08
25 Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet 2011 1.07
26 Capecitabine: have we got the dose right? Nat Clin Pract Oncol 2008 1.02
27 Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol 2005 0.99
28 Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004 0.99
29 A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer 2003 0.98
30 EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer 2012 0.92
31 Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002 0.89
32 Challenges of cancer control in developing countries: current status and future perspective. Future Oncol 2011 0.87
33 CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des 2003 0.86
34 Colorectal cancer. Acta Oncol 2003 0.85
35 Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target 2003 0.85
36 Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2009 0.84
37 Tobacco: deadly in any form or disguise. Lancet 2006 0.83
38 Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol 2010 0.82
39 Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer 2003 0.81
40 Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther 2003 0.80
41 Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci 2006 0.80
42 Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol 2009 0.80
43 Ras as a target in cancer therapy. Crit Rev Oncol Hematol 2002 0.80
44 Gene therapy for colorectal cancer. Br Med Bull 2002 0.79
45 Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol 2010 0.79
46 The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol Med 2004 0.78
47 The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer 2013 0.78
48 Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med 2010 0.76
49 Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. J Drug Target 2007 0.76
50 Gene profiling in early stage disease. Cancer J 2010 0.76
51 Health diplomacy: a new approach to the Muslim world? Global Health 2014 0.75
52 Malignant peritoneal mesothelioma. Is there a new treatment? Rare Tumors 2009 0.75
53 EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities. Eur J Pharm Sci 2005 0.75
54 Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther 2002 0.75
55 Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opin Drug Metab Toxicol 2015 0.75
56 The emergence of 'omics for the management of colorectal cancer. Curr Opin Oncol 2011 0.75
57 Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet 2005 0.75
58 Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 2007 0.75